Literature DB >> 19010855

Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial.

Kazuo Koyanagi1, Anton J Bilchik, Sukamal Saha, Roderick R Turner, David Wiese, Martin McCarter, Perry Shen, Linda Deacon, David Elashoff, Dave S B Hoon.   

Abstract

PURPOSE: Nodal micrometastasis and circulating tumor cells detected by multimarker quantitative real-time reverse transcription-PCR (qRT-PCR) may have prognostic importance in patients with colorectal cancer. EXPERIMENTAL
DESIGN: Paraffin-embedded sentinel lymph nodes from 67 patients and blood from 34 of these patients were evaluated in a prospective multicenter trial of sentinel lymph node mapping in colorectal cancer. Sentinel lymph nodes were examined by H&E staining and cytokeratin immunohistochemistry. Sentinel lymph nodes and blood were examined by a four-marker qRT-PCR assay (c-MET, melanoma antigen gene-A3 family, beta1-->4-N-acetylgalactosaminyltransferase, and cytokeratin-20); qRT-PCR results were correlated with disease stage and outcome.
RESULTS: In H&E-negative sentinel lymph node patients that recurred, cytokeratin immunohistochemistry and qRT-PCR detected metastasis in 30% and 60% of patients, respectively. Disease-free survival differed significantly by multimarker qRT-PCR upstaged sentinel lymph node (P = 0.014). qRT-PCR analysis of blood for circulating tumor cells correlated with overall survival (P = 0.040).
CONCLUSION: Molecular assessment for micrometastasis in sentinel lymph node and blood specimens may help identify patients at high risk for recurrent colorectal cancer, who could benefit from adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010855      PMCID: PMC2586882          DOI: 10.1158/1078-0432.CCR-08-0290

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

1.  Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence.

Authors:  D S Hoon; P Bostick; C Kuo; T Okamoto; H J Wang; R Elashoff; D L Morton
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

Review 2.  Scatter-factor and semaphorin receptors: cell signalling for invasive growth.

Authors:  Livio Trusolino; Paolo M Comoglio
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

3.  Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes.

Authors:  I Miyashiro; C Kuo; K Huynh; A Iida; D Morton; A Bilchik; A Giuliano; D S Hoon
Journal:  Clin Chem       Date:  2001-03       Impact factor: 8.327

4.  Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients.

Authors:  Robert Rosenberg; Axel Hoos; James Mueller; Patricia Baier; Dominik Stricker; Martin Werner; Hjalmar Nekarda; Jörg-Rüdiger Siewert
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

5.  Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial.

Authors:  A J Bilchik; S Saha; D Wiese; J A Stonecypher; T F Wood; S Sostrin; R R Turner; H J Wang; D L Morton; D S Hoon
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

6.  Technical details of sentinel lymph node mapping in colorectal cancer and its impact on staging.

Authors:  S Saha; D Wiese; J Badin; T Beutler; D Nora; B K Ganatra; D Desai; S Kaushal; M Nagaraju; M Arora; T Singh
Journal:  Ann Surg Oncol       Date:  2000-03       Impact factor: 5.344

7.  Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis.

Authors:  A J Bilchik; D Nora; R A E M Tollenaar; C J H van de Velde; T Wood; R Turner; D L Morton; D S B Hoon
Journal:  Eur J Cancer       Date:  2002-05       Impact factor: 9.162

8.  Prognostic significance of occult metastases in colon cancer.

Authors:  Arend E H Merrie; André M van Rij; Elizabeth R Dennett; Lynne V Phillips; Kankatsu Yun; John L McCall
Journal:  Dis Colon Rectum       Date:  2003-02       Impact factor: 4.585

Review 9.  Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.

Authors:  Cornelis J A Punt; Marc Buyse; Claus-Henning Köhne; Peter Hohenberger; Roberto Labianca; Hans J Schmoll; Lars Påhlman; Alberto Sobrero; Jean-Yves Douillard
Journal:  J Natl Cancer Inst       Date:  2007-06-27       Impact factor: 13.506

10.  Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.

Authors:  Taku Nakagawa; Steve R Martinez; Yasufumi Goto; Kazuo Koyanagi; Minoru Kitago; Tatsushi Shingai; David A Elashoff; Xing Ye; Frederick R Singer; Armando E Giuliano; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

View more
  35 in total

Review 1.  Biology and significance of circulating and disseminated tumour cells in colorectal cancer.

Authors:  Gunnar Steinert; Sebastian Schölch; Moritz Koch; Jürgen Weitz
Journal:  Langenbecks Arch Surg       Date:  2012-02-15       Impact factor: 3.445

2.  Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.

Authors:  Marco Wendel; Lyudmila Bazhenova; Rogier Boshuizen; Anand Kolatkar; Meghana Honnatti; Edward H Cho; Dena Marrinucci; Ajay Sandhu; Anthony Perricone; Patricia Thistlethwaite; Kelly Bethel; Jorge Nieva; Michel van den Heuvel; Peter Kuhn
Journal:  Phys Biol       Date:  2012-02-03       Impact factor: 2.583

3.  Circulating Tumor Cells and Colorectal Cancer.

Authors:  Joshua E Allen; Wafik S El-Deiry
Journal:  Curr Colorectal Cancer Rep       Date:  2010-10-01

Review 4.  CTC enumeration and characterization: moving toward personalized medicine.

Authors:  Angela Toss; Zhaomei Mu; Sandra Fernandez; Massimo Cristofanilli
Journal:  Ann Transl Med       Date:  2014-11

Review 5.  Prognostic biological features in neck dissection specimens.

Authors:  Julia A Woolgar; Asterios Triantafyllou; James S Lewis; Jennifer Hunt; Michelle D Williams; Robert P Takes; Lester D R Thompson; Pieter J Slootweg; Kenneth O Devaney; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-15       Impact factor: 2.503

6.  IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers.

Authors:  Tao Fu; Emmanouil P Pappou; Angela A Guzzetta; Marilia de Freitas Calmon; Lifeng Sun; Alexander Herrera; Fan Li; Christopher L Wolfgang; Stephen B Baylin; Christine A Iacobuzio-Donahue; Weidong Tong; Nita Ahuja
Journal:  Ann Surg       Date:  2016-02       Impact factor: 12.969

7.  Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.

Authors:  Sojun Hoshimoto; Mark B Faries; Donald L Morton; Tatsushi Shingai; Christine Kuo; He-Jing Wang; Robert Elashoff; Nicola Mozzillo; Mark C Kelley; John F Thompson; Jeffrey E Lee; Dave S B Hoon
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

8.  Intranodal Mapping Using Carbon Dye Results in More Accurate Lymph Node Staging in Colon Cancer Patients.

Authors:  Benjamin Weixler; Rene Warschkow; Andreas Zettl; Hans-Martin Riehle; Ulrich Guller; Carsten T Viehl; Markus Zuber
Journal:  World J Surg       Date:  2015-10       Impact factor: 3.352

Review 9.  Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review.

Authors:  G Peach; C Kim; E Zacharakis; S Purkayastha; P Ziprin
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

10.  Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.

Authors:  Sojun Hoshimoto; Tatsushi Shingai; Donald L Morton; Christine Kuo; Mark B Faries; Kelly Chong; David Elashoff; He-Jing Wang; Robert M Elashoff; Dave S B Hoon
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.